Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

Phase 1 Completed 27 enrolled Janssen Pharmaceutical K.K.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess pharmacodynamics and safety of JNJ-212082 in order to select the recommended dose of JNJ-212082 for patients with castration resistant prostate cancer.

Timeline

Start: 2010-06-01
Primary completion: 2014-10-02
Completion: 2014-10-02

Publications

Matsubara N, Uemura H, Fukui I, Niwakawa M, Yamaguchi A, Iizuka K, Akaza H. Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistant prostate cancer. Cancer Sci. 2014 Oct;105(10):1313-20. doi: 10.1111/cas.12496. Epub 2014 Oct 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abiraterone acetate	Small molecule	250 mg	Oral
Subject	Abiraterone acetate	Small molecule	500 mg	Oral
Subject	Abiraterone acetate	Small molecule	1000 mg	Oral

Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications